Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Publication Type:

Journal Article

Source:

The lancet oncology, Volume 15, Issue 9, p.986-96 (2014)

Keywords:

2014, Center-Authored Paper, Clinical Research Division, Flow Cytometry Core Facility, July 2014, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Specimen Processing Core Facility

Abstract:

Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia. However, randomised trials in which it was combined with standard induction chemotherapy in adults have produced conflicting results. We did a meta-analysis of individual patient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia.